Cellular Analysis of Clones A and B in VCANDAPI Staining

Jul 03, 2025

10 likes | 120 Vues

This study involves the examination of clones A and B through VCANDAPI staining, providing insights into cellular characteristics. Supplementary Figure 3 from Desjardins et al. showcases the intricate details observed in the cellular analysis, shedding light on potential differences between the two clones.

Share Presentation

Embed Code

yaakov

Télécharger la présentation

Cellular Analysis of Clones A and B in VCANDAPI Staining

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Desjardins, et. al., Supplementary Figure 3 Scrsh Clone 5 Clone 6 A VCANDAPI VCAN DAPI B

Supplementary Figure 4 Hori et al.

One-dimensional gel electrophoresis (SDS-PAGE)

108 views • 1 slides

Supplementary Figure 7 Hori et al.

A. ~70. 75. ~65. 50. 5-20% ePAGEL (Anti-phospho (T514) CRMP2 antibody). B. 75. ~70. 50. 5-20% ePAGEL (Anti-phospho (S522) CRMP2 antibody). Western blot analysis of the anti-phosphorylated CRMP2 proteins cross-reacting proteins

170 views • 1 slides

Thiruchelvam et al Supplementary Figure 4

A. B. C. D. Thiruchelvam et al Supplementary Figure 4.

79 views • 1 slides

Mertens et al., Supplementary Figure

Mertens et al., Supplementary Figure.

74 views • 1 slides

Uppalapati et al. , Supplementary Figure 3

Uppalapati et al. , Supplementary Figure 3.

79 views • 1 slides

Supplementary Figure S1 Wang et. al.

Supplementary Figure S1 Wang et. al. Pre-sort. Post-sort. a. 10 5. 4.12. 0.07. 10 4. WT. 10 3. 10 2. 0. 10 5. 5.47. 0.16. 10 4. Bim /. 10 3. 10 2. CD25. 0. 0. 10 2. 10 3. 10 4. 10 5. 0. 10 2. 10 3. 10 4. 10 5. Foxp3. b. Bim /. WT. 10 5. 10 4. 10 3. 10 2.

135 views • 4 slides

Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand.

109 views • 1 slides

Nakayama et al. , Supplementary Figure 3

Nakayama et al. , Supplementary Figure 3. HNF4G/ACTB (microarray). HNF4G/ACTB (qRT-PCR). 0.035. 2.0. 0.030. 1.5. 0.025. 0.020. 1.0. 0.015. 0.010. 0.5. 0.005. 0.000. 0.0. SS043. SS043. SS043. SS043. SS043. SS043. SS046. SS046. SS046. SS046. SS046. SS046. SS049. SS049.

75 views • 1 slides

Farmer et al Supplementary Figure 1

Farmer et al Supplementary Figure 1. [ KU0058684] (  M). 1. 2. 0. 1. 0. 0. IC 50 = 1nM. 0.00001. 0.0001. KU0051529 PARP-1 IC 50 = 730nM. 0.001. 0.01. 8. 0. 0.1. 100. 10. 0. 1. % activity. 6. 0. 4. 0. 2. 0. 0. 10 -6. 10 -5. 10 -4. 10 -3. 10 -2. 10 -1. 10 0.

226 views • 7 slides

Supplementary Figure 1. Suzuki et al.

BrdU. DAPI/BrdU. 24 hrs. 24 hrs. 48 hrs. 48 hrs. 72 hrs. 72 hrs. Supplementary Figure 1. Suzuki et al. A. B. Supplementary Figure 2. Suzuki et al. p. CPD. H2AX. Merge. p. (6-4) photo. H2AX. Merge. p. XRCC1. H2AX. Merge. Supplementary Figure 3. Suzuki et al. No UV. 3 min.

200 views • 8 slides

Yoon et al. Supplementary Figure S4

Yoon et al. Supplementary Figure S4. A. B. AGS. MKN-45. N87. AGS. MKN-45. N87. Monolayer. Monolayer. Spheroid/ Scr.shRNA. Spheroid/ DMSO. Spheroid/ Smo.shRNA. Spheroid/ Vismodegib. C. AGS. MKN-45. N87. Monolayer. Spheroid/ DMSO. Spheroid/ Vismodegib. 50 μ m.

116 views • 1 slides

Supplementary Figure 1 Logan et al

IP Ab. HSF1. we. Irr. p63. HSF1 Int. I. II. III. IV. V. F/l.  Pro. 1-292. 248-393. 1-42. TAD DBD Oligo. +. +. 248-393. 1-42. 1-292.  Pro. GST. Inputs. F/l. +. -. -. Pull down. Supplementary Figure 1 Logan et al.

117 views • 4 slides

Ruhanen et al., Supplementary Figure 3

Mt-1 (R2). Mt-2 (R2). dsRNA:. Sc. Sc. LIII. LIII. DNA ligase III. HSP 60. Ruhanen et al., Supplementary Figure 2. A. Control. r 0 cells. Gel image of double-stranded DNA arc under UV illuminator. B. Control. r 0 cells. Southern hybridisation.

126 views • 1 slides

Supplementary Figure S1, Schneider et al

Supplementary Figure S1, Schneider et al. Fully migrated out of seeded (FM ratio). A. medium. WT sup. total PBMC. NS. KO sup. medium. NS. NS. NS. NS. WT sup. lymphocytes. NS. KO sup. medium. monocytes. WT sup. NS. KO sup. 0. 10. 20. 30. 40. 50. FM ratio (%).

135 views • 1 slides

Yang et al. Supplementary Figure S1

pAWF-DIAP1. CG7023. CG5384. CG5603. CG7288. CG12082. CG8830. CG5798. CG5505. CG8494. CG4165. CG30421. CG3781. CG4968. CG9448. CG14884. vec. pAMW. 150. 150. 100. 100. 75. 75. 50. 50. FLAG (DIAP1). 37. 37. 25. 25. 20. 20. Actin. Yang et al. Supplementary Figure S1.

108 views • 1 slides

Oiva et al., Supplementary Figure.

Oiva et al., Supplementary Figure. P < 0.0001. 1000. P < 0.0001. 100. Trypsinogen-3 (  g/L). 10. 1. 0.1. Mild AP. Severe AP. Controls.

150 views • 1 slides

Supplementary Figure 5. Nikolova et al

Supplementary Figure 5. Nikolova et al.

93 views • 1 slides

Supplementary Figure 1_Van Looy et al.

77 views • 1 slides

Desjardins, et. al., Supplementary Figure 4

Desjardins, et. al., Supplementary Figure 4. *.

74 views • 1 slides

Sansone et al, Supplementary Figure 2

HYPO-7. A. 1 MONTH 6 MONTHS 1 YEAR. B. c. 1 MONTH 6 MONTHS 1 YEAR. HYPO-7. MCF-7 + - + - + - HYPO-7 - + - + - +. DFX 600 m M - +. CA-IX.

252 views • 1 slides

Gentile et al., Supplementary Figure 6

A. B. C. Cell Density (Arbitrary Units). D. Cell Density (Arbitrary Units). Gentile et al., Supplementary Figure 6

111 views • 1 slides

Supplementary figure 1 Palacios et. al

E-cadherin. Transferrin. Merge. 35 °C/ 4hrs. Supplementary figure 1 Palacios et. al. 0 4 8 12 0 4 8 12. Hours of v-Src activation. Extracellular domain epitope Cytoplasmic domain epitope. { Anti-E-cadherin. Supplementary figure 2

97 views • 2 slides

More Related